131 related articles for article (PubMed ID: 28111925)
1. Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.
Modak S; Kushner BH; Basu E; Roberts SS; Cheung NK
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28111925
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.
Wagner LM; Villablanca JG; Stewart CF; Crews KR; Groshen S; Reynolds CP; Park JR; Maris JM; Hawkins RA; Daldrup-Link HE; Jackson HA; Matthay KK
J Clin Oncol; 2009 Mar; 27(8):1290-6. PubMed ID: 19171709
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.
Hasselbalch B; Lassen U; Hansen S; Holmberg M; Sørensen M; Kosteljanetz M; Broholm H; Stockhausen MT; Poulsen HS
Neuro Oncol; 2010 May; 12(5):508-16. PubMed ID: 20406901
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.
Moreno L; Weston R; Owens C; Valteau-Couanet D; Gambart M; Castel V; Zwaan CM; Nysom K; Gerber N; Castellano A; Laureys G; Ladenstein R; Rössler J; Makin G; Murphy D; Morland B; Vaidya S; Thebaud E; van Eijkelenburg N; Tweddle DA; Barone G; Tandonnet J; Corradini N; Chastagner P; Paillard C; Bautista FJ; Gallego Melcon S; De Wilde B; Marshall L; Gray J; Burchill SA; Schleiermacher G; Chesler L; Peet A; Leach MO; McHugh K; Hayes R; Jerome N; Caron H; Laidler J; Fenwick N; Holt G; Moroz V; Kearns P; Gates S; Pearson ADJ; Wheatley K;
J Clin Oncol; 2024 Apr; 42(10):1135-1145. PubMed ID: 38190578
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.
Wagner LM; Perentesis JP; Reid JM; Ames MM; Safgren SL; Nelson MD; Ingle AM; Blaney SM; Adamson PC
Pediatr Blood Cancer; 2010 Apr; 54(4):538-45. PubMed ID: 20049936
[TBL] [Abstract][Full Text] [Related]
6. VIncristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma.
Setty BA; Stanek JR; Mascarenhas L; Miller A; Bagatell R; Okcu F; Nicholls L; Lysecki D; Gupta AA
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28748602
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.
Reardon DA; Vredenburgh JJ; Coan A; Desjardins A; Peters KB; Gururangan S; Sathornsumetee S; Rich JN; Herndon JE; Friedman HS
J Neurooncol; 2011 Dec; 105(3):621-7. PubMed ID: 21744079
[TBL] [Abstract][Full Text] [Related]
8. Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter?
Raiser P; Schleiermacher G; Gambart M; Dumont B; Defachelles AS; Thebaud E; Tandonnet J; Pasqualini C; Proust S; Entz-Werle N; Aerts I; Ndounga-Diakou LA; Petit A; Puiseux C; Khanfar C; Rouger J; Mansuy L; Benadiba J; Millot F; Pluchart C; Laghouati S; Geoerger B; Vassal G; Valteau-Couanet D; Berlanga P
Eur J Cancer; 2024 May; 202():114001. PubMed ID: 38489858
[TBL] [Abstract][Full Text] [Related]
9. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor.
Park MS; Patel SR; Ludwig JA; Trent JC; Conrad CA; Lazar AJ; Wang WL; Boonsirikamchai P; Choi H; Wang X; Benjamin RS; Araujo DM
Cancer; 2011 Nov; 117(21):4939-47. PubMed ID: 21480200
[TBL] [Abstract][Full Text] [Related]
10. Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab-irinotecan in children with low-grade glioma?
Heng MA; Padovani L; Dory-Lautrec P; Gentet JC; Verschuur A; Pasquier E; Figarella-Branger D; Scavarda D; André N
Cancer Med; 2016 Jul; 5(7):1542-5. PubMed ID: 27037940
[TBL] [Abstract][Full Text] [Related]
11. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study.
London WB; Frantz CN; Campbell LA; Seeger RC; Brumback BA; Cohn SL; Matthay KK; Castleberry RP; Diller L
J Clin Oncol; 2010 Aug; 28(24):3808-15. PubMed ID: 20660830
[TBL] [Abstract][Full Text] [Related]
12. Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA.
Anderson P; Ghisoli M; Crompton BD; Klega KS; Wexler LH; Slotkin EK; Stanbery L; Manning L; Wallraven G; Manley M; Horvath S; Bognar E; Nemunaitis J
Clin Cancer Res; 2023 May; 29(9):1689-1697. PubMed ID: 36780200
[TBL] [Abstract][Full Text] [Related]
13. Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma.
Cole KA; Ijaz H; Surrey LF; Santi M; Liu X; Minard CG; Maris JM; Voss S; Reid JM; Fox E; Weigel BJ
Cancer; 2023 Jul; 129(14):2245-2255. PubMed ID: 37081608
[TBL] [Abstract][Full Text] [Related]
14. Intraoperative Radiation Therapy for Relapsed or Refractory High-Risk Neuroblastoma: A 27-Year Experience.
Conte B; Casey DL; Tringale KR; Honeyman J; Narayan NJC; LaQuaglia MP; Gerstle JT; Modak S; Kushner BH; Kramer K; Wolden SL
Pract Radiat Oncol; 2024; 14(3):e226-e232. PubMed ID: 38310488
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial.
Hogarty MD; Ziegler DS; Franson A; Chi YY; Tsao-Wei D; Liu K; Vemu R; Gerner EW; Bruckheimer E; Shamirian A; Hasenauer B; Balis FM; Groshen S; Norris MD; Haber M; Park JR; Matthay KK; Marachelian A
Br J Cancer; 2024 Mar; 130(5):788-797. PubMed ID: 38200233
[TBL] [Abstract][Full Text] [Related]
16. Irinotecan dose schedule for the treatment of Ewing sarcoma.
Slotkin EK; Meyers PA
Pediatr Blood Cancer; 2023 Jan; 70(1):e30005. PubMed ID: 36184748
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group.
Villablanca JG; London WB; Naranjo A; McGrady P; Ames MM; Reid JM; McGovern RM; Buhrow SA; Jackson H; Stranzinger E; Kitchen BJ; Sondel PM; Parisi MT; Shulkin B; Yanik GA; Cohn SL; Reynolds CP
Clin Cancer Res; 2011 Nov; 17(21):6858-66. PubMed ID: 21908574
[TBL] [Abstract][Full Text] [Related]
18. Opaganib Downregulates N-Myc Expression and Suppresses In Vitro and In Vivo Growth of Neuroblastoma Cells.
Maines LW; Keller SN; Smith RA; Schrecengost RS; Smith CD
Cancers (Basel); 2024 May; 16(9):. PubMed ID: 38730731
[TBL] [Abstract][Full Text] [Related]
19. Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update.
Bautista F; Fioravantti V; de Rojas T; Carceller F; Madero L; Lassaletta A; Moreno L
Cancer Med; 2017 Nov; 6(11):2606-2624. PubMed ID: 28980418
[TBL] [Abstract][Full Text] [Related]
20. A Chart Review on the Feasibility and Safety of the Vincristine Irinotecan Pazopanib (VIPaz) Association in Children and Adolescents With Resistant or Relapsed Sarcomas.
Russo I; Di Paolo V; Crocoli A; Mastronuzzi A; Serra A; Di Paolo PL; Di Giannatale A; Miele E; Milano GM
Front Oncol; 2020; 10():1228. PubMed ID: 32850366
[No Abstract] [Full Text] [Related]
[Next] [New Search]
